The multidrug resistance (mdr) genes encode P-glycoproteins, integral membrane proteins which function as drug efflux transporters. Exposure of animals in vivo and cells in vitro to a variety of xenobiotics leads to increased mdr1 gene expression and higher levels of P-glycoprotein. This response may protect cells from the cytotoxic effects of these compounds. In this investigation we functionally expressed the rat mdr1b gene in NIH 3T3 cells and assessed the ability of the encoded P-glycoprotein to protect these cells from the cytotoxicity of xenobiotics known to induce mdr1b expression. In long-term colony survival assays, stably expressed mdr1b conferred resistance to cytotoxic drugs such as colchicine, vinblastine and doxorubicin, but not to 5-fluorouracil nor to the carcinogens aflatoxin B 1 and N-hydroxy-acetylaminofluorene. The mdr reversal agent verapamil restored cytotoxicity of colchicine, doxorubicin, actinomycin D, vinblastine and taxol, but had no effect on the sensitivity of these cells to 5-fluorouracil, aflatoxin B 1 or N-hydroxy-acetylaminofluorene. In a competitive transport assay, verapamil and, to a lesser extent, colchicine blocked the increased efflux of the fluorescent dye rhodamine 123 from mdr1b-transfected cells, whereas aflatoxin B 1 did not compete for this export. These data demonstrate that expression of the rat mdr1b encoded P-glycoprotein can protect cells from a diverse group of compounds previously identified to be mdr substrates, however, other effective inducers of mdr expression, such as aflatoxin B 1 and N-hydroxy-acetylaminofluorene, remain potent cytotoxins despite high levels of P-glycoprotein. The fact that compounds which are not themselves substrates can induce P-glycoprotein expression may have implications for pharmacokinetic interactions and chemotherapy.
Introduction
Many laboratories are investigating the regulation of the multidrug resistance genes (mdr*) and the mechanism by which the encoded protein, P-glycoprotein (P-gp), causes cells to become resistant to a variety of cytotoxic drugs (reviewed in 1-3). Human P-gp is a membrane glycoprotein of~170 kDa. This polypeptide is comprised of two symmetrical halves each with six putative membrane spanning regions and an ATP binding domain (1, 3) . Acting as an ATP-dependent drug efflux pump, P-gp lowers the intracellular concentration of many cytotoxic drugs permitting cells to survive exposure to drug concentrations that would otherwise be lethal. P-gp may also function to lower drug influx to increase cell survival. Emergence of multidrug resistance is common in many human tumors and is often due to overexpression of P-gp (4) . Thus, this protein is both biochemically interesting and potentially important for successful therapy with cancer chemotherapeutic drugs.
In humans there are two P-gps encoded by distinct MDR genes, MDR1 and MDR2 (alternatively referred to as MDR3). Rodents have two functional homologs of MDR1, mdr1a and mdr1b, and one homolog of MDR2, mdr2. The P-gp encoded by MDR1 is associated with drug efflux and perhaps transport of short chain lipids, whereas the P-gp encoded by MDR2 has recently been identified as a phosphatidylcholine transporter (5) (6) (7) (8) . Expressed normally on the luminal side of epithelial cells of the intestine, liver, pancreas and blood-brain barrier, one possible physiological function of the MDR1 encoded P-gp is to serve as a protective barrier or export mechanism for toxins (9, 10) . Recent support for this hypothesis comes from the use of mice in which the mdr1a gene was disrupted by homologous recombination (11) . Upon challenge with xenobiotics, these mice experience central nervous system toxicity and accumulate high amounts of drugs in their brain, indicating a central role for the mdr1a encoded P-gp in the blood-brain barrier. These animals also have increased sensitivity to chemotherapeutic drugs such as vinblastine.
One hallmark of P-gp-mediated multidrug resistance is the ability of this protein to transport a wide range of structurally and mechanistically diverse compounds. In general, drugs which are substrates for P-gp tend to be large, aromatic and lipophilic (1, 3) . The list of compounds which interact with P-gp is large and continually expanding. Of particular relevance are many common anticancer agents such as colchicine, taxol, Vinca alkaloids, anthracyclines and epipodophyllotoxins. In contrast, antimetabolite drugs such as 5-fluorouracil (5-FU) and platinum compounds such as cisplatin tend to be more hydrophilic and are not substrates for P-gp. Increased levels of mdr mRNA and P-gp have been observed in rat liver and isolated hepatocytes following exposure to xenobiotics such as 2-acetylaminofluorene, 3-methylcholanthrene, aflatoxin B 1 (AFB 1 ) and cycloheximide (12) (13) (14) (15) . However, these compounds have not been tested for transport by P-gp.
In the present experiments we examined the ability of the P-gp encoded by the rat mdr1b gene to confer resistance to the cytotoxicity of carcinogens which have previously been observed to be strong inducers of mdr1b expression. The mouse, hamster and human mdr1 encoded P-gps have been characterized for their ability to transport cytotoxic drugs and confer resistance (16) (17) (18) (19) , however, the rat protein has not yet been investigated. Since the rat is widely used for investigations on chemical carcinogenicity and drug metabolism, a detailed knowledge of the function of rat P-gp is important for this Fig. 1 . Expression of mdr1b mRNA and P-gp in rat liver following exposure to AFB 1 . (A) RNase protection assay of RNA isolated from rat liver at 0-24 h following exposure to AFB 1 . Rat liver total RNA (10 µg) was simultaneously hybridized to the mdr1b and GAPDH probes and the RNase protection analysis was performed as described in Materials and methods. (B) Western blot analysis of membrane proteins isolated from rat livers at the indicated time points. P-gp expression was revealed with C219 primary antibody (1 µg/ml) and ECL as described in Materials and methods. model system. The data presented here demonstrate that the rat mdr1b encoded P-gp protects against the cytotoxicity of prototypical P-gp substrates, therefore, this gene should now be considered a functional member of the mdr gene family. Furthermore, despite being strong inducers of mdr mRNA, the carcinogens AFB 1 and N-hydroxy-acetylaminofluorene (N-OH-AAF) are not transported by P-gp and overexpression of P-gp is insufficient to protect cells from their cytotoxic effects. Thus, the ability of xenobiotics to induce mdr expression is not correlated with functional protection of cells by P-gp.
Materials and methods

Treatment of animals
Male Fischer 344 rats (150-250 g) were maintained on a 12 h light/dark cycle and fed standard laboratory chow ad libitum. AFB 1 (1 mg/kg) was administered by i.p. injection 0-72 h prior to sacrifice. RNA was isolated from the 
RNase protection assay
The level of RNA expression in the liver was determined by the RNase protection assay method as previously described (13, 21) . Quantitation of mRNA and normalization of mdr to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was performed by phosphorimager analysis with ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
mdr1b expression vectors
The cDNA encoding the rat mdr1b gene (22) was cloned into the EcoRI site of phagemid vector pBK-CMV (Stratagene, La Jolla, CA) according to standard procedures (23) . Forward and reverse orientations of the pBK-CMV/ mdr1b constructs were characterized by restriction mapping and dideoxy sequencing with Sequenase version 2.0 (US Biochemical, Cleveland, OH). Nucleotide sequences were analyzed with the PCGene software package (Intelligenetics, Mountain View, CA).
Cell culture
Mouse NIH 3T3 fibroblasts (American Type Culture Collection, Rockville, MD) were cultured in Dulbecco's modified Eagle's medium supplemented with 4.5 g/l glucose, 4 mM glutamine, 50 µg/ml gentamicin, 10% fetal bovine serum at 37°C in 5% CO 2 . The cells were stably transfected in 6-well plates (250 000 cells/well) with 1 µg pBK-CMV/mdr1b (in either orientation) and native pBK-CMV using lipofectamine and Opti-MEM serum-/antibioticfree medium according to the manufacturer's instructions (Gibco BRL/Life Technologies, Gaithersburg, MD). After 12 h the medium was replaced with DMEM containing fetal bovine serum for 48 h and then the transfected cells were selected with 400 µg/ml active G418. As an additional indication of transfection efficiency, G418-resistant clones were subsequently screened for sensitivity to 100 nM colchicine, based on previous dose-response curves with parental NIH 3T3 cells. Low concentrations (7.5 nM) of colchicine were used in the culture medium to maintain selective pressure on stable mdr1b transfectants. The sensitivities of pBK-CMV/mdr1b reverse orientation and pBK-CMV transfectants to colchicine were identical, therefore only the latter were used for further experiments. All cell cultures were routinely split 1:10 every week and replaced with new aliquots from frozen stocks after eight passages.
Northern blot analysis
Total RNA from parental and transfected cell lines was extracted using a RNA-STAT kit according to the manufacturer's instructions (Tel-Test B Inc., Friendswood, TX). Twenty micrograms of each RNA sample were separated on a 1% agarose gel and transferred onto a nylon membrane (ICN, Irvine, CA). The blots were probed for the mdr1b gene with a single exon probe 2257 corresponding to nt 3594-3797 (22), stripped and reprobed for GAPDH to normalize mdr RNA expression. Hybridizations were executed in QuikHyb solution as indicated by the manufacturer (Stratagene, La Jolla, CA) and blots were analyzed with a phosphorimager.
Western blot analysis
Isolation of a crude membrane fraction from rat livers or from NIH 3T3 parental and transfected cell lines was essentially performed according to methods previously described (24, 25) . Thirty micrograms of membrane proteins were separated on an 8% SDS-polyacrylamide gel and transferred to a 0.45 µm nitrocellulose membrane as described previously (25) . Equal loading conditions were confirmed in each case by staining the blots with Ponceau-S. The blots were blocked in TBS-T containing 5% skimmed milk for 1 h, probed with 1 µg/ml C219 antibody (Signet Laboratories, Dedham, MA) in TBS-T for 2 h and visualized by enhanced chemiluminescence (ECL) according to the manufacturer's instructions (Amersham, Arlington Heights, IL). The mdr1b transfectant with higher P-gp expression (clone 2) was used for all the functional assays described hereafter.
Colony survival assay
To investigate stable drug resistance conferred by the mdr1b gene, low passage parental NIH 3T3 as well as pBK-CMV and pBK-CMV/mdr1b transfectants were harvested, tested for viability by trypan blue dye exclusion and seeded in triplicate in 100 mm Petri dishes at densities of 10 2 -10 6 per dish for each drug tested. After incubation for 8 h in complete medium to allow cell attachment, the cytotoxic drugs were added to the medium at the indicated final concentrations (colchicine, 10-300 nM; 5-FU, 0.1-100 µM; AFB 1 , 0.1-3 µM; N-OH-AAF, 10-300 µM). The cells were incubated until appearance of colonies (between 10 and 12 days), which were washed in phosphatebuffered saline, fixed in 95% ethanol and stained with hematoxylin. Colonies with Ͼ50 cells were considered survivors and counted with an Artek counter model 880 (Artek Systems Co., Farmingdale, NY). The plating efficiency of each cell line was calculated from the number of colonies contained in untreated control dishes seeded with 10 2 and 10 3 cells and subsequently maintained in complete medium with 0.1% dimethylsulfoxide. Survival was calculated as the number of colonies in treated dishes divided by the plating efficiency. The values obtained represent the mean (ϮSEM) of three independent experiments with triplicate dishes and are expressed as percentages of survival in untreated dishes.
Cytotoxicity assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) survival assay was used to assess whether rat mdr1b conferred the mdr phenotype to transfected cells. Parental NIH 3T3, as well as pBK-CMV and pBK-CMV/mdr1b transfectants, were seeded in 96-well plates at 3ϫ10 3 cells/ well. After 8 h each plate was treated with medium containing increasing concentrations of one of the following cytotoxic drugs: vinblastine (5-500 nM); colchicine (30-3000 nM); doxorubicin (0.1-10 µM); actinomycin D (ACT D, 3-300 nM); taxol (10-1000 nM); 5-FU (0.1-10 µM); AFB 1 (30-3000 nM); N-OH-AAF (3-300 µM). The reversibility of the mdr phenotype was evaluated in separate plates in which the medium also contained 10 µM verapamil. After 96 h cell survival was measured using the CellTiter 96™ non-radioactive cell proliferation assay, according to the manufacturer's instructions (Promega, Madison, WI). Absorbance of the MTT formazan product was read at 570 nM with a Dynatech MR 5000 ELISA reader and analyzed with Biolynx software (Dynatech Laboratories, Chantilly, VA). The data are the mean (ϮSEM), expressed as percentages of viability in untreated cells, and are representative of at least three independent experiments.
Rhodamine 123 efflux
To avoid damaging mdr activity with trypsin, 2ϫ10 6 parental or mdr1b-transfected NIH 3T3 cells were harvested with versene solution (Gibco BRL/ Life Technologies, Gaithersburg, MD) and gentle agitation (26) . After washing with complete medium and ensuring 90% viability, the cells were incubated with 1 µg/ml rhodamine 123 (Rh123) for 30 min at 37°C, maintaining the suspension by constant, gentle shaking. The cells were washed twice with ice-cold medium and incubated again at 37°C in Rh123-free medium alone or containing one of the following drugs for efflux inhibition studies: verapamil (10 µM); AFB 1 (1 µM); colchicine (250 nM). After a 90 min incubation the cells were washed, stained with propidium iodide and kept on ice until further Propidium iodide staining to gate out dead cells revealed no cytotoxic effects under the experimental conditions described above. The cell fluorescence analyzed immediately after staining and transferring cells to dye-free medium (time 0) was used as the control value for each sample. A cursor was positioned to the left of this fluorescence peak to identify cells that had effluxed Rh123 and the median fluorescence was utilized to quantify dye content on a linear scale using Lysis II software (Becton-Dickinson). Intracellular dye retention was expressed as a percentage of the value obtained at time 0. After flow cytometry the intracellular accumulation of Rh123 was confirmed fluorimetrically on butanol-extracted samples as previously described (27; data not shown). 
Results
Induction of mdr1b mRNA and P-gp in rat liver after AFB 1 administration
We previously demonstrated that exposure of rats in vivo and isolated hepatocytes in vitro to a number of xenobiotics, such as 2-acetlyaminofluorene and its metabolites, 3-methylcholanthrene and cycloheximide, results in a dose-and timedependent increase in mdr1b expression which is due to an increase in transcription (13) (14) (15) 28) . Similarly, exposure of rats to AFB 1 (1 mg/kg) resulted in an increase in mdr1b mRNA levels in the livers of these animals ( Figure 1A) . As revealed by RNase protection assay, AFB 1 induced a 3-to 4-fold increase in mdr1b expression by 24 h following treatment. Concomitantly, increased levels of P-gp (3-to 4-fold by densitometric analysis) were also observed by Western blot analysis of membrane proteins isolated from aflatoxin-treated livers ( Figure 1B) . Thus exposure to AFB 1 in vivo results in both increased mdr mRNA and P-gp levels. Generation of cell lines expressing the rat mdr1b gene To examine the relationship between inducers of mdr1b expression and the ability of the encoded P-gp to confer resistance to cytotoxins, we constructed cell lines which stably express the rat mdr1b gene. The rat mdr1b cDNA (22) was inserted into the pBK-CMV mammalian expression vector and then transfected into NIH 3T3 cells. Colonies were selected with G418 and then screened for resistance to 100 nM colchicine to evaluate transfection efficiency. Several resistant cell lines were derived and further tested for the presence and expression of the rat mdr1b gene. Northern blot analysis of RNA isolated from three independent mdr1b-transfected cell lines indicated increased expression of mdr1b (Figure 2A ). In contrast, mdr1b expression was undetectable in control NIH 3T3 cells, cells transfected with the empty vector and cells transfected with the mdr1b gene in the reverse orientation. Rehybridization of this membrane demonstrated equivalent RNA loading in each lane, as expression of GAPDH was similar in all cell lines. Translation of the transfected mdr1b gene in these cells was confirmed by Western blot analysis. P-gp was undetectable in control NIH 3T3 cells, whereas two independent transfected cell lines had significant levels of the protein ( Figure 2B ). Immunohistochemical staining of mdr1b-transfected cells revealed increased P-gp present in the plasma membrane compared with the parental cell line (data not shown). These data demonstrate that the NIH 3T3-mdr1b cells harbor the rat mdr1b gene, which is actively transcribed and translated into P-gp.
Effect of mdr1b expression on resistance to cytotoxic agents
Resistance of the stably transfected NIH 3T3-mdr1b cells to multiple cytotoxic agents was determined using a colony survival assay. mdr1b transfectants were significantly more resistant to the cytotoxicity of colchicine versus the parental NIH 3T3 or vector-transfected cells ( Figure 3A) . At 100 nM colchicine the NIH 3T3-mdr1b cells remained 85% viable, whereas fewer than 1% of control cells survived. Similar data were observed with vinblastine and doxorubicin (data not shown). Conversely, the mdr1b-expressing cells, the vector-transfected and parental NIH 3T3 cells were equally sensitive to 5-FU, a compound which is not a substrate for P-gp ( Figure 3B ). We next determined if expression of mdr1b conferred resistance to the carcinogens AFB 1 and N-OH-AAF. The NIH 3T3-mdr1b cells and the control cells had similar sensitivity to AFB 1 and N-OH-AAF ( Figure  3C and D respectively). These data suggest that expression of P-gp is insufficient to protect these cells from the cytotoxic effect of these carcinogens and that despite being strong inducers of mdr expression (13-15,28,29 and this report) these compounds are not substrates for P-gp.
Rat mdr1b confers the mdr phenotype but not resistance to AFB 1 or N-OH-AAF
To confirm that P-gp was involved in resistance to the chemotherapeutic agents but not the carcinogens, we examined the effect of the mdr reversal agent verapamil (1) on the cytotoxicity of these agents. Exposure of the NIH 3T3-mdr1b cells to vinblastine resulted in~10-fold greater resistance over parental NIH 3T3 or pBK-CMV-transfected cells ( Figure 4A ). Concurrent treatment with verapamil eliminated the resistant phenotype of these cells, restoring their sensitivity to levels identical to the parental cells. Similarly, NIH 3T3-mdr1b cells were resistant to the cytotoxic effect of higher doses of colchicine than control cells and this resistance was reversed by addition of verapamil ( Figure 4B) . Thus, the resistance exhibited by these cells to vinblastine and colchicine is likely due to increased levels of mdr1b encoded P-gp. Comparable results were also obtained with other substrates for P-gp, such as doxorubicin, ACT D and taxol ( Figure 4C-E) . In contrast, the mdr1b-and pBK-CMV-transfected cells were equally sensitive to the antimetabolite 5-FU and to the cytotoxic effects of the carcinogens AFB 1 and N-OH-AAF (Figures 4F-H) . In each case addition of verapamil did not increase the cytotoxicity of these agents. These data further support the hypothesis that P-gp does not confer resistance to the cytotoxic effects of these carcinogens.
AFB 1 does not compete for mdr1b-induced Rh123 efflux
Export of the fluorescent dye Rh123, a cationic lipophilic compound, has been used as a measurement of P-gp mediated transport (26, (30) (31) (32) . We used this compound in a competitive transport assay to see if AFB 1 could block Rh123 transport in the transfected cell lines. Accumulation of Rh123 was significantly lower in NIH 3T3-mdr1b cells than in vectortransfected and parental cells ( Figure 5 ). Efflux of Rh123 from mdr1b-transfected cells was blocked by verapamil and, to a lesser extent, by colchicine. In contrast, these agents had no effect on Rh123 retention in the parental or mock-transfected cells. AFB 1 did not compete for Rh123 transport in either the transfected cells or parental cells, suggesting that AFB 1 is not a substrate for P-gp.
Discussion
The present study was undertaken to achieve two major objectives. The first was to establish if the P-gp encoded by the rat mdr1b gene was a functional member of the multidrug resistance gene family. Second, we examined whether carcinogens which induce mdr expression are functionally transported by P-gp. The ability of the mdr1 genes to confer resistance upon transfection into drug-sensitive cells has been well documented with the human MDR1 and murine mdr1a (mdr3) and mdr1b (mdr1) genes (16) (17) (18) (19) . Transfection and subsequent expression of the mdr1 gene has been observed to be sufficient to convey resistance to cytotoxic drugs such as colchicine, vinblastine and doxorubicin. Similarly, the hamster pgp1 gene has recently been transfected into Chinese hamster lung cells and demonstrated to encode a functional P-gp (33) . The rat mdr1b gene is highly homologous to mdr genes isolated from other species, with the highest degree of identity with the murine mdr1b gene (22) . Thus, based on this high degree of conservation, it is reasonable to expect that this gene would be functionally active in conferring drug resistance. The data presented here indeed demonstrate that expression of the P-gp encoded by the rat mdr1b gene in drug-sensitive cells is sufficient to confer resistance to established mdr substrate drugs that have unrelated structures and modes of action, such as colchicine, vinblastine, doxorubicin, ACT D and taxol. Furthermore, resistance to these cytotoxic drugs is reversed by verapamil, an established inhibitor of P-gp. Combined, these data demonstrate for the first time that the rat mdr1b gene is a functional member of this gene family.
We and others have previously demonstrated that xenobiotics induce expression of the mdr genes. In rat liver isolated primary hepatocytes and in rat hepatoma cells expression of mdr1b is increased by exposure to AFB 1 (see this report for induction in rat liver) and carcinogenic aromatic amines, including AAF and its reactive metabolite N-OH-AAF (13) (14) (15) (34) (35) (36) . This increase requires metabolic activation of the carcinogens and is the result of increased gene transcription (13) (14) (15) 29, 36) . In this regard, it is important to note that AFB 1 has been shown to be metabolized and cause DNA adducts, mutations and toxicity in cells with similar lineage to the cells used in our investigation (37, 38) . The observation that AFB 1 is toxic to our cell lines in a concentration range comparable with or even lower than that used in these previous studies (37, 38) strongly suggests that these cells are capable of metabolizing this compound to its reactive forms. Other cytotoxic drugs, such as adriamycin, daunomycin and mitoxantrone, also increase mdr gene expression in rodent cells (39) . Heat shock and sodium arsenite regulate expression of the human MDR1 gene via an increase in transcription (40) . Cytotoxic drugs, heat shock and UV light also activate the MDR1 promoter in both stable and transient transfection assays (41) (42) (43) (44) (45) . Recently a role for the EGR1 transcription factor has 2261 been suggested in modulating MDR1 promoter activity in hematopoietic cells in response to the tumor promoter 12-Otetradecanoylphorbol-13-acetate (46) . However, the precise mechanism by which cytotoxins induce mdr gene expression remains to be defined.
Increased mdr expression in response to cytotoxic agents is now well established, however, the transport of many compounds by P-gp has not been determined. Chemotherapeutic drugs such as colchicine, vinblastine, doxorubicin and daunomycin are both inducers of mdr expression as well as substrates for P-gp (39, 44) . In addition, Yeh et al. observed that P-gp mediates removal of the carcinogen benzo[a]pyrene in an adriamycin-selected MCF-7 carcinoma cell line (47) . However, other carcinogens which induce mdr expression have not yet been investigated to see if they are transported. In the current study we demonstrate that AFB 1 , a potent inducer of mdr1b expression, is not transported by P-gp and does not compete for transport of Rh123. Increased expression of P-gp also does not confer resistance to N-OH-AAF, another potent inducer of mdr1b expression (15, 29, 36) . Chaudhary and Roninson observed that chemotherapeutic agents such as cisplatin, 5-FU and hydroxyurea, which are not substrates of P-gp, increased MDR1 expression in a subpopulation (3-10%) of K562 leukemia cells (48) . It has also been reported that several chemosensitizers stimulate the ATPase activity of P-gp but are not substrates for transport (reviewed in 49). It is interesting to note that in contrast to the compounds employed in these previous studies, AFB 1 and N-OH-AAF are large, aromatic and lipophilic and so appear able to fulfil the structural requirements for typical P-gp substrates (1, 3) . Therefore, regardless of their physicochemical properties, agents which induce mdr expression and activity are not necessarily substrates for transport by P-gp, suggesting that the requirements for mdr inducers are less strict than those for mdr substrates.
Although P-gp is not strictly co-regulated with the cytochrome P4501A gene, as was originally proposed, we and others have suggested that P-gp is one component of cellular detoxification and defense mechanisms (12, 13) . It is likely that induction of mdr occurs along with numerous other genes as part of an overall cellular response to stress. This may explain why cellular stresses other than P-gp substrates, such as heat shock and UV light (40, 41, 43, 45) , induce mdr promoter transcription. Indeed, our previous investigations showing no specific carcinogen-responsive element in the rat mdr1b promoter (14) , along with the current results with AFB 1 and N-OH-AAF, suggest that induction of the mdr1b gene may result from an increase in transcription factors responsive to DNA damage induced by these carcinogens (50) (51) (52) . Moreover, two other multidrug resistance-related genes, MRP and cMOAT, have recently been observed to be important in removing conjugated compounds from cells and may also have a role in cellular protective mechanisms (53, 54) .
The fact that compounds which are not in themselves substrates can induce P-gp levels has practical implications for chemotherapy. Clearly, the range of compounds which has been identified to induce mdr expression extends beyond that of cancer chemotherapeutics and suggests that serious pharmacokinetic interactions may result from co-administration of these drugs (55, 56) . Recent identification of clinically administered drugs which interact with drug metabolizing enzymes, in particular CYP3A, as well as P-gp, further suggests that interactions between these proteins may have profound effects on interindividual variations in pharmacokinetics and therapeutic response.
